Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.

Chronic Telogen Effluvium may resolve after years and is diagnosed by examining the patient's history and clinical signs, with treatment aimed at underlying causes and possibly minoxidil.

Scalp biopsies from dermatomyositis patients show chronic hair loss without scarring, with mucin and blood vessel changes being very common.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Nivolumab can cause hair loss as a rare side effect.

Mice with alopecia areata had wider lymphatic vessels in their skin.

The document explains different hair and scalp conditions, including common hair loss after pregnancy or illness, drug-induced hair loss, hereditary excessive hair growth, patterned baldness, autoimmune hair loss, and permanent loss due to skin disease, with generally limited treatment options.

Stem cell treatment improved hair density in female hair loss patient.

People with alopecia areata often have thyroid autoimmunity.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

Botulinum A toxin injections reduced pain and promoted hair regrowth in a woman with a rare form of alopecia areata.

Better documentation of alopecia areata in Black individuals is needed to improve diagnosis.

A woman's sudden hair loss three years after a bone marrow transplant was a sign of chronic graft-versus-host disease but improved with treatment.

PRP and IT are equally effective for treating localized alopecia areata, but PRP causes more pain and bleeding.

Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.

Combining DPCP with PRP doesn't improve hair regrowth in alopecia areata.

Alopecia areata affects about 1.93% of people worldwide, with more women affected than men.

Telogen effluvium is a hair loss condition caused by various factors and requires a thorough examination to diagnose and differentiate from other hair loss types.

Female pattern hair loss is linked to genetics, family history, and lifestyle factors.

Obstetrician/gynecologists can diagnose and manage female hair loss with careful history taking and examination.

The guideline provides recommendations for managing alopecia areata effectively.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

Certain hair and scalp features indicate a worse outcome in alopecia areata.

The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.

A thorough assessment and combined treatment are crucial for managing complex alopecia, especially in patients with skin of color.

The most common cause of hair loss in children is tinea capitis, followed by alopecia areata and telogen effluvium.

The document concludes that various childhood hair and nail disorders exist, some may improve on their own, and advances in genetics and immunology could enhance treatment and counseling.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

Lichen planopilaris is a chronic, scarring hair loss condition with no definitive cure, requiring accurate diagnosis and treatment to manage symptoms.